logo
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program

RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program

Yahoo10-06-2025
BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies.
RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules.
'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Dr.Ramkesh Meena, MD, CEO of RenaissThera.
RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan.
About RenaissThera
RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages India's CRO ecosystem for early-stage R&D to deliver globally relevant innovation.
For more information www.renaissthera.com
Please contact:
Media: Lakshmi Ramakrishna lramakrishna@renaissthera.com
Investor & Partnership: Ramkesh Meena bd@renaissthera.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

JSW Cement lists at Rs 153.50, posts 4.4% gains over IPO price
JSW Cement lists at Rs 153.50, posts 4.4% gains over IPO price

Business Upturn

time11 minutes ago

  • Business Upturn

JSW Cement lists at Rs 153.50, posts 4.4% gains over IPO price

Shares of JSW Cement made a positive debut on Monday, listing at ₹153.50 apiece — up 4.42% from the upper end of its IPO price band of ₹147. The Mumbai-based cement maker's IPO, open from August 7 to August 11, was priced in the range of ₹139-147 per share with a lot size of 102 shares. The company raised ₹3,600 crore, comprising a fresh issue of ₹1,600 crore and an offer-for-sale of ₹2,000 crore (13.60 crore shares). The issue saw an overall subscription of 7.77 times, with QIBs subscribing 15.80 times, NIIs 10.97 times, and retail investors 1.81 times. Employee quota was also fully subscribed. Analysts note that the brand's strong recall and stable demand outlook helped deliver a good listing despite modest oversubscription. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.

COHR Earnings: Coherent Stock Crashes 16% on Disappointing Guidance
COHR Earnings: Coherent Stock Crashes 16% on Disappointing Guidance

Business Insider

time39 minutes ago

  • Business Insider

COHR Earnings: Coherent Stock Crashes 16% on Disappointing Guidance

The stock of Coherent (COHR) is down 16% after the semiconductor company reported revenue guidance that disappointed Wall Street. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The Pennsylvania-based company announced earnings per share (EPS) of $1, which topped the $0.92 expected among analysts. Revenue for the year's second quarter totaled $1.53 billion, which was ahead of the $1.51 billion forecast on Wall Street. Sales were up 16% from a year earlier. Unfortunately, Coherent's revenue guidance overshadowed what was otherwise a strong print from the optical materials and semiconductor concern. For the current quarter, Coherent said that it expects revenue of $1.53 billion, which is basically the same as sales generated in Q2 of this year and is 0.6% below analysts' consensus estimate. Laser Business Sale Coherent's networking business unit saw its revenue rise 39% year-over-year in calendar Q2 to $945 million, above expectations for $940 million in sales. That strong showing was partially offset by the company's other two business lines, materials and lasers, which were down a combined 8% in the quarter. Just before Coherent's latest earnings were released after markets closed, the company announced the sale of its laser business for defense markets at a price of $400 million. Money generated from the sale will be used to pay down the company's $3.7 billion in debt. Is COHR Stock a Buy? The stock of Coherent has a consensus Strong Buy rating among 15 Wall Street analysts. That rating is based on 14 Buy and one Hold recommendations issued in the last three months. The average COHR price target of $105.31 implies about 8% downside risk from current levels. These ratings are likely to change after the company's financial results.

Fed rate-cut drumbeat pegs back dollar; Asian stocks take a breather
Fed rate-cut drumbeat pegs back dollar; Asian stocks take a breather

Yahoo

time2 hours ago

  • Yahoo

Fed rate-cut drumbeat pegs back dollar; Asian stocks take a breather

By Jaspreet Kalra SINGAPORE (Reuters) -The U.S. dollar was under pressure on Thursday as traders piled into wagers that the Federal Reserve will resume cutting interest rates next month, powering Bitcoin to a record high, while a blistering rally in regional stocks took a breather. MSCI's gauge of equities in Asia excluding Japan nudged higher and lingered near its loftiest level since September 2021, taking cues from Wall Street, where the S&P 500 and Nasdaq indexes hit new closing highs for the second straight day. The MSCI All Country World Index rose to a record high for the second straight session on Wednesday. Japan's Nikkei fell after a searing six-day rally that boosted it past the 43,000 mark for the first time. Shares in Korea and Taiwan were slightly lower as well. China's blue-chip stock index and shares in Hong Kong gained. The dollar fell to a two-week low against a basket of major peers on shifting expectations of U.S. rate cuts, with comments from the U.S. Treasury Secretary also helping bolster expectations of an outsized 50 basis point cut. The Japanese yen hit a three-week high of 146.38 per dollar in early trading. [FRX/] Treasury Secretary Scott Bessent said on Wednesday that an aggressive half-point cut was possible in September after revised labour market data from last week showed that job growth had slowed sharply in May, June and July. Goldman Sachs said on Wednesday in a research note it expects the U.S. Federal Reserve to deliver three 25-basis-point interest rate cuts this year and two more in 2026. Traders are pricing in certainty of a rate cut in September with odds of a 50 bps cut rising to 7%, up from 0% a week earlier. While a tame U.S. inflation report this week boosted the case for rate cuts, some analysts have cautioned against market complacency, saying that upcoming data may alter expectations. "We're not as convinced of a 25bp FOMC rate cut in September as financial markets, let alone a 50bp rate cut," said Carol Kong, economist and currency strategist at Commonwealth Bank of Australia. "There will be another CPI and payrolls report ahead of the September meeting that can make or break the case for a rate cut," Kong said. BITCOIN, GOLD Optimism on monetary policy easing in the world's largest economy also powered cryptocurrency bitcoin to an all-time high of $124,002.49 with analysts also pointing to recent financial sector reforms as a tailwind for the asset class. Bitcoin has risen 32% so far in 2025, and the second largest cryptocurrency, Ethereum, has climbed 41% and is hovering just shy of its all-time high hit in November 2021. In commodity markets, gold prices rose 0.5% to $3,371 and crude oil prices edged up after hitting a two-month low on Wednesday as investors kept their focus on the summit between U.S. President Donald Trump and Russian leader Vladimir Putin on Friday. [O/R] [GOL/] Trump on Wednesday threatened "severe consequences" if Putin did not agree to peace in Ukraine but also said that a meeting between them could swiftly be followed by a second one that would include Ukrainian President Volodymyr Zelenskiy. In the past, Trump has said both sides will have to swap land to end fighting that has cost tens of thousands of lives and displaced millions. "While lack of progress towards a ceasefire may lead to renewed threats of secondary oil tariffs/sanctions, we see limited risk of large disruptions in Russia supply," analysts at Goldman Sachs wrote in a note. Large volumes of Russian exports, the possibility of deepening price discounts to maintain demand, and the likely eagerness of key buyers India, and especially China, to continue energy cooperation with Russia are expected to avert major disruptions, they said. Trump signed an executive order last week levying an additional 25% tariff on India's exports to the U.S., saying that the country directly or indirectly imported Russian oil. He has also hinted at similar tariffs on China.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store